Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Neuroblastoma 5Sarcoma, Ewing 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Osteosarcoma 1Medulloblastoma 1Glioma 1Glioblastoma 1Ganglioneuroblastoma 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1Brain Neoplasms 1

Interventions

Temozolomide 2tazemetostat 1talazoparib 1irinotecan sucrosofate 1etoposide phosphate 1dinutuximab 1atezolizumab 1abemaciclib 1Zoledronic Acid 1X-Rays 1Tiragolumab 1Specimen Handling 1Radiotherapy 1Radiosurgery 1Phantoms, Imaging 1Nivolumab 1Microarray Analysis 1Magnetic Resonance Spectroscopy 1Irinotecan 1Ipilimumab 1Immunohistochemistry 1Ifosfamide 1Granulocyte-Macrophage Colony-Stimulating Factor 1Fluorodeoxyglucose F18 1Eflornithine 1Dasatinib 1Carboplatin 1Blotting, Western 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Rhabdoid Tumor × dinutuximab × Clear all
NCT04238819 2026-03-02

A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma

Eli Lilly and Company

Phase 1/2 Completed
47 enrolled 36 charts
CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡